WBC
KPTI icon

West Branch Capital’s Karyopharm Therapeutics KPTI Stock Holding History

West Branch Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30 Hold
3
– – ﹤0.01% 355
2026
Q1 		$17 Hold
3
– – ﹤0.01% 377
2025
Q4 		$23 Hold
3
– – ﹤0.01% 415
2025
Q3 		$20 Hold
3
– – ﹤0.01% 452
2025
Q2 		$13 Hold
3
– – ﹤0.01% 472
2025
Q1 		$12 Hold
3
– – ﹤0.01% 530
2024
Q4 		$33 Hold
3
– – ﹤0.01% 546
2024
Q3 		$40 Hold
3
– – ﹤0.01% 600
2024
Q2 		$42 Hold
3
– – ﹤0.01% 429
2024
Q1 		$73 Hold
3
– – ﹤0.01% 422
2023
Q4 		$42 Buy
+3
New +$40 ﹤0.01% 442

Other funds holding KPTI

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
MLA
MB, Levis & Associates Center Valley, Pennsylvania $271M AUM 15.56% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

West Branch Capital's KPTI Position: Q2 2026 in Review

West Branch Capital held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 3 shares worth $30. The position accounts for ﹤0.01% of the portfolio, ranked #355.

West Branch Capital first reported a position in KPTI in Q4 2023 and has held it in 11 quarters since. The position peaked at $73 in Q1 2024. 6 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • West Branch Capital held 3 shares of Karyopharm Therapeutics worth $30 as of Q2 2026.
  • West Branch Capital left its Karyopharm Therapeutics share count unchanged in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of West Branch Capital's portfolio in Q2 2026, its #355 holding.
  • West Branch Capital first reported a position in Karyopharm Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • West Branch Capital's Karyopharm Therapeutics position peaked at $73 in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on West Branch Capital's 13F filing for Q2 2026, filed 10 Jul 2026.